Johnson & Johnson (NYSE:JNJ) Shares Acquired by Blair William & Co. IL

Blair William & Co. IL lifted its position in Johnson & Johnson (NYSE:JNJ) by 12.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,045,546 shares of the company’s stock after purchasing an additional 114,780 shares during the quarter. Blair William & Co. IL’s holdings in Johnson & Johnson were worth $152,817,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. O Brien Greene & Co. Inc boosted its stake in Johnson & Johnson by 9.1% during the second quarter. O Brien Greene & Co. Inc now owns 9,567 shares of the company’s stock worth $1,398,000 after buying an additional 797 shares during the period. Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of Johnson & Johnson by 6.6% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 135,526 shares of the company’s stock worth $19,808,000 after acquiring an additional 8,408 shares in the last quarter. Argent Trust Co increased its holdings in Johnson & Johnson by 0.5% during the 2nd quarter. Argent Trust Co now owns 189,595 shares of the company’s stock worth $27,711,000 after purchasing an additional 963 shares during the period. Mercer Global Advisors Inc. ADV increased its stake in shares of Johnson & Johnson by 3.9% during the second quarter. Mercer Global Advisors Inc. ADV now owns 695,805 shares of the company’s stock worth $92,799,000 after buying an additional 26,174 shares during the period. Finally, E Fund Management Co. Ltd. raised its holdings in shares of Johnson & Johnson by 12.2% in the 2nd quarter. E Fund Management Co. Ltd. now owns 16,173 shares of the company’s stock valued at $2,364,000 after purchasing an additional 1,755 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on JNJ. Sanford C. Bernstein raised their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. The Goldman Sachs Group dropped their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Up 0.0 %

Shares of NYSE JNJ opened at $167.07 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The firm’s 50-day moving average is $160.38 and its two-hundred day moving average is $154.01. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a market capitalization of $402.08 billion, a PE ratio of 10.42, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.80 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 2.97%. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.